Venous thromboembolism (VTE) represents a leading cause of global mortality. Most recent clinical studies have focused on improving patient mortality using advanced hemodynamic parameters as risk stratification tools and then advanced interventions beyond the use of systemic anticoagulation, with mixed results.1,2 It is now clear that the long-term consequences of residual pulmonary thrombosis and thrombus burden in patients with acute pulmonary embolism (PE) should be evaluated. The determinants of thrombus development and thrombus resolution are incompletely understood. In vascular beds such as the infrarenal aorta, thrombus formation is hypothesized to stabilize a weakened aneurysmal wall, which may have sustained a dissection event.3,4 However, the pulmonary vascular bed appears to respond only adversely to the presence of residual thrombosis.5,6 An exaggerated hemostatic response leads to the formation of venous thrombi, obstructing blood flow and potentially causing acute and chronic symptoms as well as acute PE, which may be fatal.

A tremendous amount has been learned about VTE since Rudolf Virchow published his insightful treatise in 1856.7 Known for his early insights into mechanisms of VTE, including coining the terms embolism and thrombosis, Virchow recognized that pulmonary artery thrombosis originated mostly from venous thrombotic events in the lower extremities, stating in 1859 that “the detachment of larger or smaller fragments from the end of the softening thrombus, which are carried along by the current of blood and driven into remote vessels, gives rise to the very frequent process on which I have bestowed the name of ‘embolia.’ ”2 This work refuted the work of the French pathologist Jean Cruveilhier, who claimed that “venous phlebitis causes the formation of thrombus so that coagulation is the main consequence of venous inflammation.”8 His theory did not explain the disease in its entirety, but time and research have demonstrated that Professor Cruveilhier was more correct than he was given credit for.

Neither René Laennec nor Cruveilhier considered that PE originates in the veins of the lower extremities or pelvis, as both believed that the thrombi arose primarily in the pulmonary arteries, a view long held by many before Virchow's work. Related to this research, Virchow described the factors contributing to venous thrombosis. More theories and discoveries evolved subsequently.

What do we know about mechanisms of clot formation in 2020 and their implications for clinical management? Clinical risk factors such as surgery, trauma, acute medical illness, cancer, age, and obesity translate into VTE risk factors based on one or more of Virchow’s triad. Awareness of these risks enables evidence-based decision-making about VTE prevention. This article focuses on the hypercoagulability and venous injury/inflammation features that make these clinical risk factors important. A number of genetic and acquired risk factors have been identified for VTE that alter blood flow, activate the endothelium, and alter the activity of coagulation factors.9

GENETIC MECHANISMS

Heritability plays an obvious role in the susceptibility to acute VTE. The most impactful genetic risk factors for VTE are deficiencies of protein C, protein S, and antithrombin.10,11 These phenomena are rare in the general population but increase VTE risk by as much as 10-fold in affected individuals. A less thrombogenic group of genetic abnormalities, including non-O blood group (increased factor VIII levels), factor V Leiden mutation, prothrombin gene 20210A mutation, and fibrinogen gamma variant 10034T, increase the risk of VTE by two- to fivefold. These genetic variants are present in a small percentage of the population as “gain of function mutations” that increase the risk of venous thrombosis.11 Single nucleotide polymorphisms (SNPs), which are typically one-base variants in coding and noncoding DNA sequences, ultimately cause functional differences in protein that regulate hemostasis and thrombosis.12 Examples include SNPs in genes encoding platelet glycoprotein 6, antithrombin III (SERPINC1), and coagulation factor XI.12 The clinical implications of determining the presence of such mutations in the general population is unclear and controversial. In certain settings, in the presence of acquired and heritable gain of function aberrations in thrombosis such as the presence of antiphospholipid antibodies, testing is an important step in guiding appropriate anticoagulation therapy.13,14

INTERMEDIARY METABOLISM

Metabolic syndrome (abdominal obesity, impaired glucose metabolism, dyslipidemia, and hypertension) is associated with a procoagulant and hypofibrinolytic milieu and thus an increased risk of vascular disease and venous thrombotic events.15 Adipocytes secrete inflammatory cytokines (adipokines). Recently, Stewart et al demonstrated an association between metabolic syndrome and pulmonary artery pressure in patients with submassive PE at the time of diagnosis and after catheter-directed therapy.16 This investigation is a cautionary note that the job of the physician is far from complete at the time of treatment. Careful attention to biochemical and clinical variables involved in thrombus formation and resolution may affect long-term patient outcomes. Lipoprotein(a) [Lp(a)] has Kringle domains that resemble those in plasminogen required for fibrin binding, although it is clear that we know less about the role of Lp(a) in VTE.17,18 Meta-analyses suggest that Lp(a) is associated with an increased risk of VTE,19 but other studies have been less conclusive; perhaps the risk of VTE increases in the presence of additional risk factors.20 Larger cohort studies would be useful to resolve this question. Because antisense oligonucleotide therapy has demonstrated effectiveness in decreasing the blood concentration of Lp(a),21 greater attention will likely be directed to understanding molecular and biochemical events caused by this inflammatory, thrombogenic, and vasoactive lipoprotein.

INFLAMMATION AND THROMBOSIS

The interaction between the innate immune system and thrombosis is important for thrombus formation and resolution (Figure 1).22 Although hypothesis-driven research using randomized controlled trials is the benchmark for proving the effectiveness of new therapeutic agents, this is the final step in investigative research that cannot be reached without the efforts of our colleagues performing basic science research. Using animal models of thrombotic disease has allowed for observations in the research laboratory to be translated into humans. Physicians are reminded of the dynamic role between inflammation and thrombosis when managing conditions including diabetes, sepsis, obesity, bowel disease, acute respiratory distress syndrome, and cancer, as well as during surgical procedures. Three important cells that are potential targets for mediating “immunothrombosis” are leukocytes, platelets, and the vascular endothelium.23-28 When endothelial cells are inflamed and tight junctions are disengaged by intracellular phosphorylation events, subendothelial tissue factor (TF) is released, activating the extrinsic coagulation cascade (Figure 2). Activated endothelial cells and platelets also release Weibel-Palade bodies containing von Willebrand factor and CD62 (P-selectin), which promote platelet and leukocyte recruitment, respectively.29,30 Leukocytes also release cytokines including interleukin-1Β (IL-1Β) and IL-6, for which animal models have provided mechanistic insight.31-33 Thus, there is a clear association between VTE and inflammation.34-37

Figure 1. Cytokine and chemokine regulation of VTE. Panel A: Thrombus formation results from the interactions between endothelial cells, leukocytes, and platelets regulated by cytokines and chemokines. First, IL-6 and IL-17 induce endothelial cell activation by increasing the expression of adhesion molecules (VCAM-1, ICAM-1, and P-selectin). In addition, endothelial cells secrete CXCL2 and CCL2, promoting neutrophil and monocyte recruitment. IL-10 was found to inhibit neutrophil recruitment. P-selectin/PSGL-1 interaction and CXCR2/CXCL1 engagement cooperate to generate Β2 integrin-dependent arrest in neutrophils and NETosis. Then, interferon (IFN)-&gamma, secreted by natural killer (NK) cells, and IL-17 promote NET formation and induce venous thrombosis. In parallel, IL-17 and IL-9 regulate platelet activation and aggregation through the expression of CD61 and P-selectin. CCL2-recruited monocytes/macrophages secrete IL-1Β, also contributing to platelet aggregation. Panel B: Thrombus resolution, characterized by fibrinolysis, collagenolysis, and neovascularization, is regulated by tumor necrosis factor (TNF)-α and IFN-&gamma. TNF-α increases MMP-2/MMP-9 and urokinase plasminogen activator (uPA) expression, leading to collagenolysis and fibrinolysis, respectively. In contrast, IFN-&gamma produced by effector-memory T cells has detrimental roles in thrombus resolution by suppressing collagenolysis and neovascularization. Ultimately, uncontrolled inflammation leads to VTE chronicity in part through TGF-Β and IL-6. TGF-Β secreted by platelets signals via TGF-Β RI to promote endothelial dysfunction and subsequently collagen deposition. IL-6 released by activated endothelial cells is proposed to exert profibrotic effects after deep vein thrombosis through CCL2 upregulation. The latter generates monocyte recruitment and CCL2 secretion leading to collagen deposition. Reproduced with permission from Najem MY, Couturaud F, Lemarie CA. Cytokine and chemokine regulation of venous thromboembolism. J Thromb Haemost. 2020;18:1009-1019. doi: 10.1111/jth.14759

Figure 2. The interface and interconnection between coagulation and inflammation, a process exemplified by SARS-CoV-2 infection—“immunothrombosis.”

Although a more detailed discussion is beyond the scope of this article, it deserves mention that the recent COVID-19 pandemic has clearly demonstrated the presence of in situ thrombosis (ie, thrombosis without the requirement for an embolic event), making the case clear for the immunothrombotic phenomenon and the IL-6 receptor a rational therapeutic target for the humanized antibody tocilizumab.38 Another fascinating observation in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the presence of neutrophil extracellular traps (NETs).39 NETs are extracellular DNA fibers extruded from neutrophils produced in response to infection, allowing the neutrophils to “trap” and eliminate invading microorganisms. However, NETs are a prominent feature of patients testing positive for the COVID-19 amplicon and in patients infected with another single-stranded RNA influenza B.40-48 NETs appear to be involved in the activation of platelets, activation of the extrinsic and intrinsic coagulation cascades, and inhibition of antithrombin III.49,50

CANCER-ASSOCIATED THROMBOSIS

The principal fibrin-forming mechanism underlying cancer-associated thrombosis is considered to be upregulation of TF expression in cancer cells and cancer cell–derived membrane vesicles.51 Although a detailed discussion is outside the scope of this article, it seems likely that the TF/factor VIIa pathway is a principal initiator of fibrin formation in cancer patients.52,53 Cancer cells express TF on their plasma membrane and release TF-bearing procoagulant microparticles into the circulation. Furthermore, polyphosphate/factor XII–triggered coagulation has been demonstrated in prostate cancer–associated thrombosis.54 Tumors have been shown to release molecules, including adenosine triphospate, that activate the platelet P2Y12 receptor, and platelet-derived mediators have also been shown to regulate tumor growth.55,56

FUTURE THERAPEUTIC TARGETS FOR THROMBUS RESOLUTION

It is clear that many patients with residual PE remain symptomatic, and it is the authors’ belief that clot extraction and/or augmenting early thrombus resolution in carefully selected patients are tantamount to avoiding thrombus-mediated pulmonary artery remodeling and vascular dysfunction. Clinicians and basic scientists must make a concerted effort to delineate signal transduction pathways in cells that regulate thrombus formation and resolution. The composition of a thrombus includes fibrin, red blood cells (erythrocytes), platelets, and leukocytes. Long-term and current aspirin use was shown not to alter right ventricular strain or pulmonary thrombus burden using the Qanadli score for pulmonary artery thrombus burden in a small study,57 yet targeting other pathways in the platelet may improve thrombus resolution in certain conditions. In a murine model of VTE, endothelial but not platelet transforming growth factor–Β1 signaling was proposed as a critical determinant of thrombus resolution.58 Venous thrombus was shown to secrete matrix metalloproteinases (MMPs) that can remodel veins, and activated platelet-derived MMPs are found in extracted thrombus and in the circulating blood in patients with acute thrombotic events.59,60 Erythrocytes, like platelets and the vascular endothelium, produce nitric oxide (NO), which has anti-inflammatory, antithrombotic, and antiproliferative properties.61 Erythrocyte-derived NO can alter vascular tone and regulate thrombosis in various vascular beds.62 As the hematocrit rises, bleeding time shortens.63 Therefore, erythrocytes can also tip the balance toward thrombosis in certain conditions such as polycythemia vera and perhaps even prolonged intravascular depletion.

CONCLUSION

Although there is a critical relationship between inflammation and thrombosis, the complex interactions, time course, and specific origin of various cytokines and chemokines involved in the development of VTE remain obscure. It is becoming clearer, as with the arterial side of cardiovascular disease, that unresolved inflammation in acute thrombosis could be critical in the evolution of acute and chronic venous thrombosis. The future is exciting, but many questions remain.

1. Secemsky E, Chang Y, Jain CC, et al. Contemporary management and outcomes of patients with massive and submassive pulmonary embolism. Am J Med. 2018;131:1506-1709.e0. doi: 10.1016/j.amjmed.2018.07.035

2. Chaudhury P, Gadre SK, Schneider E, et al. Impact of multidisciplinary pulmonary embolism response team availability on management and outcomes. Am J Cardiol. 2019;124:1465-1469. doi: 10.1016/j.amjcard.2019.07.043

3. Piechota-Polanczyk A, Jozkowicz A, Nowak W, et al. The abdominal aortic aneurysm and intraluminal thrombus: current concepts of development and treatment. Front Cardiovasc Med. 2015;2:19. doi: 10.3389/fcvm.2015.00019

4. Mower WR, Quiñones WJ, Gambhir SS. Effect of intraluminal thrombus on abdominal aortic aneurysm wall stress. J Vasc Surg. 1997;26:602-608. doi: 10.1016/s0741-5214(97)70058-2

5. Hosokawa K, Ishibashi-Ueda H, Kishi T, et al. Histopathological multiple recanalized lesion is critical element of outcome after pulmonary thromboendarterectomy. Int Heart J. 2011;52:377-381. doi: 10.1536/ihj.52.377

6. Kim NH, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2012;21:27-31. doi: 10.1183/09059180.00009111

7. Molenaar JC. [From the library of the Netherlands Journal of Medicine. Rudolf Virchow: Die Cellularpathologie in ihrer Begrundung auf physiologische und pathologische Gewebelehre; 1858] [Article in Dutch]. Ned Tijdschr Geneeskd. 2003;147:2236-2244.

8. Sakuta M. [One hundred books which built up neurology (35)—Cruveilhier J “Anatomie Pathologique du Corps Humain” (1829-1842)] [Article in Japanese]. Brain Nerve. 2009;61:1354-1355.

9. Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012;122:2331-2336. doi: 10.1172/JCI60229

10. Lipe B, Ornstein DL. Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin. Circulation. 2011;124:e365-368. doi: 10.1161/CIRCULATIONAHA.111.044412

11. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 1. Thromb Haemost. 1996;76:651-662.

12. Morange PE, Suchon P, Trégouët, D.A. Genetics of venous thrombosis: update in 2015. Thromb Haemost. 2015;114:910-919. doi: 10.1160/TH15-05-0410

13. Sebastiani GD, Iuliano A, Cantarini L, Galeazzi M. Genetic aspects of the antiphospholipid syndrome: an update. Autoimmun Rev. 2016;15:433-439. doi: 10.1016/j.autrev.2016.01.005

14. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365-1371. doi: 10.1182/blood-2018-04-848333

15. Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost. 2006;4:1914-1918. doi: 10.1111/j.1538-7836.2006.02132.x

16. Stewart LK, Beam DM, Casciani T, et al. Effect of metabolic syndrome on mean pulmonary arterial pressures in patients with acute pulmonary embolism treated with catheter-directed thrombolysis. Int J Cardiol. 2020;302:138-142. doi: 10.1016/j.ijcard.2019.12.043

17. Chiva-Blanch G, Badimon L. Cross-talk between lipoproteins and inflammation: the role of microvesicles. J Clin Med. 2019;8:2059. doi: 10.3390/jcm8122059

18. Hervio L, Durlach V, Girard-Globa A, Anglés-Cano E. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry. 1995;34:13353-13358. doi: 10.1021/bi00041a011

19. Dentali F, Gessi V, Marcucci R, et al. Lipoprotein(a) as a risk factor for venous thromboembolism: a systematic review and meta-analysis of the literature. Semin Thromb Hemost. 2017;43:614-620. doi: 10.1055/s-0036-1598002

20. Kunutsor SK, Makikallio TH, Kauhanen J, et al. Lipoprotein(a) is not associated with venous thromboembolism risk. Scand Cardiovasc J. 2019;53:125-132. doi: 10.1080/14017431.2019.1612087

21. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244-255. doi: 10.1056/NEJMoa1905239

22. Najem MY, Couturaud F, Lemarie CA. Cytokine and chemokine regulation of venous thromboembolism. J Thromb Haemost. 2020;18:1009-1019. doi: 10.1111/jth.14759

23. Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation. 2004;110(24 suppl 1):IV4-12. doi: 10.1161/01.CIR.0000150639.98514.6c

24. Monn MF, Hui X, Lau BD, et al. Infection and venous thromboembolism in patients undergoing colorectal surgery: what is the relationship? Dis Colon Rectum. 2014;57:497-505. doi: 10.1097/DCR.0000000000000054

25. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39:559-566. doi: 10.1055/s-0033-1343894

26. Lentz SR. Thrombosis in the setting of obesity or inflammatory bowel disease. Blood. 2016;128:2388-2394. doi: 10.1182/blood-2016-05-716720

27. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007;5 suppl 1:246-254. doi: 10.1111/j.1538-7836.2007.02497.xx

28. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133:906-918. doi: 10.1182/blood-2018-11-882993

29. Morrell CN, Matsushita K, Chiles K, et al. Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci U S A. 2005;102:3782-3787. doi: 10.1073/pnas.0408310102

30. Matsushita K, Morrell CN, Cambien B, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003;115:139-150. doi: 10.1016/s0092-8674(03)00803-1

31. Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. Front Pediatr. 2018;6:142. doi: 10.3389/fped.2018.00142

32. Budnik I, Brill A. Immune factors in deep vein thrombosis initiation. Trends Immunol. 2018;39:610-623. doi: 10.1016/j.it.2018.04.010

33. Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: cause or consequence? Int Immunopharmacol. 2015;28:655-665. doi: 10.1016/j.intimp.2015.07.044

34. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost. 2009;102:615-619. doi: 10.1160/TH09-04-0274

35. Gao Q, Zhang P, Wang W, et al. The correlation analysis of tumor necrosis factor-alpha-308G/A polymorphism and venous thromboembolism risk: a meta-analysis. Phlebology. 2016;31:625-631. doi: 10.1177/0268355515607405

36. Mosevoll KA, Johansen S, Wendelbo O, et al. Cytokines, adhesion molecules, and matrix metalloproteases as predisposing, diagnostic, and prognostic factors in venous thrombosis. Front Med (Lausanne). 2018;5:147. doi: 10.3389/fmed.2018.00147

37. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res. 2001;89:1-2. doi: 10.1161/hh1301.093825

38. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117:10970-10975. doi: 10.1073/pnas.2005615117

39. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5:138999. doi: 10.1172/jci.insight.138999

40. Klok FA, Kruip MJ, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147. doi: 10.1016/j.thromres.2020.04.013

41. Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. Published online April 24, 2020. doi: 10.1161/CIRCULATIONAHA.120.047430

42. Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis. 2020;96:467-474. doi: 10.1016/j.ijid.2020.05.055

43. Long AT, Kenne E, Jung R, et al. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost. 2016;14:427-437.

44. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012;32:1777-1783. doi: 10.1161/ATVBAHA.111.242859

45. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107:15880-15885. doi: 10.1073/pnas.1005743107

46. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34-45. doi: 10.1038/nri3345

47. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci. 2010;67:499-511. doi: 10.1007/s00018-009-0205-1

48. Koupenova M, Corkrey HA, Vitseva O, et al. The role of platelets in mediating a response to human influenza infection. Nat Commun. 2019;10:1780. doi: 10.1038/s41467-019-09607-x

49. Noubouossie DF, Whelihan MW, Yu YB, et al. In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood. 2017;129:1021-1029. doi: 10.1182/blood-2016-06-722298

50. Thalin C, Hisada Y, Lundstrom S, et al. Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis. Arterioscler Thromb Vasc Biol. 2019;39:1724-1738. doi: 10.1161/ATVBAHA.119.312463

51. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11:223-233. doi: 10.1111/jth.12075

52. Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122:1873-1880. doi: 10.1182/blood-2013-04-460139

53. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119:924-932. doi: 10.1182/blood-2011-06-317685

54. Nickel KF, Ronquist G, Langer F, et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood. 2015;126:1379-1389. doi: 10.1182/blood-2015-01-622811

55. Cho MS, Noh K, Haemmerle M, et al. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood. 2017;130:1235-1242. doi: 10.1182/blood-2017-02-769893

56. Lee EC, Cameron SJ. Cancer and thrombotic risk: the platelet paradigm. Front Cardiovasc Med. 2017;4:67. doi: 10.3389/fcvm.2017.00067

57. Van Galen J, Pava L, Wright C, et al. Effect of platelet inhibitors on thrombus burden in patients with acute pulmonary embolism. Platelets. Published online March 6, 2020. doi: 10.1080/09537104.2020.1732329

58. Bochenek ML, Leidinger C, Rosinus NS, et al. Activated endothelial TGF-beta1 signaling promotes venous thrombus nonresolution in mice via endothelin-1: potential role for chronic thromboembolic pulmonary hypertension. Circ Res. 2020;126:162-181. doi: 10.1161/CIRCRESAHA.119.315259

59. Deatrick KB, Eliason JL, Lynch EM, et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg. 2005;42:140-148. doi: 10.1016/j.jvs.2005.04.014

60. Schmidt RA, Morrell CN, Ling FS, et al. The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from non-ST-segment elevation myocardial infarction. Transl Res. 2018;195:1-12. doi: 10.1016/j.trsl.2017.11.006

61. Gladwin MT. How red blood cells process nitric oxide: evidence for the nitrite hypothesis. Circulation. 2017;135:177-179. doi: 10.1161/CIRCULATIONAHA.116.024752

62. Bailey DM, Rasmussen P, Overgaard M, et al. Nitrite and S-nitrosohemoglobin exchange across the human cerebral and femoral circulation: relationship to basal and exercise blood flow responses to hypoxia. Circulation. 2017;135:166-176. doi: 10.1161/CIRCULATIONAHA.116.024226

63. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272-4290. doi: 10.1182/blood-2001-12-0349

Scott J. Cameron, MD, PhD
Associate Section Head for Research
Section of Vascular Medicine
Department of Cardiovascular Medicine
Cleveland Clinic Foundation
Cleveland, Ohio
cameros3@ccf.org
Disclosures: None.

Victor F. Tapson, MD
Director, Venous Thromboembolism and
Pulmonary Vascular Disease Research
Director of Clinical Research, Women’s Guild Lung Institute
Associate Director, Pulmonary Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California
victor.tapson@cshs.org
Disclosures: Research funding (to institution) from Bayer, Bristol-Myers Daiichi, Squibb, Janssen, Penumbra; consulting/advisory boards for Arena, Bayer, Bristol-Myers Squibb, Inari Medical, Janssen, Penumbra.